Mylan Generic Infringes Sanofi's Uroxatral Patent: Judge

Law360, New York (May 17, 2010, 5:42 PM EDT) -- A federal judge has given Sanofi-Aventis SA a boost in its multidistrict litigation over competitors' attempts to market a generic version of prostate treatment Uroxatral, ruling at trial that the drug proposed by Mylan Pharmaceutical Inc. would in fact infringe Sanofi’s patent.

On Friday, Judge Gregory M. Sleet of the U.S. District Court for the District of Delaware finalized an earlier oral ruling from the bench that Mylan’s generic alfuzosin hydrochloride would infringe U.S. Patent Number 4,661,491, dashing the generic-drug maker’s contention that the patent is...
To view the full article, register now.